Healthcare · Pharmaceuticals & Biotechnology
The largest companies in the same industry by market cap. This company ranks #110 of 184. PE, ROE, 1Y return and scores come from the daily/weekly precomputed snapshot.
| Company | Market cap (₹ Cr) | PE (TTM) | ROE | 1Y return | Div. yield | Quality | Valuation | Momentum |
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | 427,010 | 143.5 | 13.7% | 7.6% | — | 72 | 8 | 30 |
| Divi's Laboratories Limited | 244,125 | 83.0 | 15.3% | 57.8% | 0.33% | 70 | 4 | 51 |
| Torrent Pharmaceuticals Limited | 161,506 | 77.7 | 12.2% | 35.3% | 0.80% | 56 | 0 | 31 |
| Zydus Lifesciences Limited | 113,616 | 32.6 | 17.3% | 14.5% | 0.09% | 74 | 24 | 84 |
| Cipla Limited | 107,888 | 35.1 | 11.2% | -11.7% | 0.97% | 73 | 29 | 62 |
| Laurus Labs Limited | 106,505 | 122.0 | 17.1% | 128.4% | — | 78 | 24 | 53 |
| Mankind Pharma Limited | 102,382 | 46.9 | 11.7% | 0.9% | — | 68 | 12 | 86 |
| Dr. Reddy's Laboratories Limited | 100,411 | 150.9 | 10.9% | -3.7% | — | 62 | 33 | 71 |
| Lyka Labs Limited (this stock) | 280 | — | -11.5% | -19.1% | — | 31 | 54 | 53 |
| Period end | Revenue (₹ Cr) | PBT (₹ Cr) | Net profit (₹ Cr) | Basic EPS |
|---|---|---|---|---|
| June 30, 2026 | 42 | 2 | 2 | ₹ |
| March 31, 2026 | 28 | -9 | -8 | ₹ |
| Dec. 31, 2025 | 31 | -0 | -0 | ₹ |
| Sept. 30, 2025 | 37 | -4 | -3 | ₹ |
| June 30, 2025 | 33 | 1 | 1 | ₹ |
| March 31, 2025 | 33 | 3 | 2 | ₹ |
| Dec. 31, 2024 | 34 | 4 | 3 | ₹ |
| Sept. 30, 2024 | 41 | 3 | 2 | ₹ |
| June 30, 2024 | 30 | 2 | 1 | ₹ |
| March 31, 2024 | 28 | -2 | -2 | ₹ |
| Dec. 31, 2023 | 33 | 3 | 2 | ₹ |
| Sept. 30, 2023 | 28 | -1 | -1 | ₹ |
| June 30, 2023 | 23 | -2 | -2 | ₹ |
The detailed income statement is standalone-only: the consolidated feed carries just revenue, PBT and net profit.
| Year ended | Revenue (₹ Cr) | PBT (₹ Cr) | Net profit (₹ Cr) |
|---|---|---|---|
| March 31, 2026 | 128 | -12 | -10 |
| March 31, 2025 | 138 | 11 | 8 |
| March 31, 2024 | 111 | -1 | -3 |
| March 31, 2023 | 93 | -13 | -13 |
Data unavailable.
| Year ended | Operating (₹ Cr) | Investing (₹ Cr) | Financing (₹ Cr) | Capex (₹ Cr) | Free Cash Flow (₹ Cr) |
|---|---|---|---|---|---|
| March 31, 2026 | 5 | -9 | 4 | 11 | -6 |
| March 31, 2025 | 2 | -12 | 5 | 16 | -14 |
| March 31, 2024 | 2 | -9 | 2 | 9 | -7 |
| March 31, 2023 | 9 | 7 | -22 | 8 | 1 |
| March 31, 2022 | 79 | 9 | -64 | -8 | 87 |
| Year ended | Total Assets (₹ Cr) | Total Equity (₹ Cr) | Reserves (₹ Cr) | Borrowings, Current (₹ Cr) | Borrowings, Non-current (₹ Cr) | Current Assets (₹ Cr) | Current Liabilities (₹ Cr) | Cash & Equivalents (₹ Cr) | Net Block (₹ Cr) | Inventory (₹ Cr) |
|---|---|---|---|---|---|---|---|---|---|---|
| March 31, 2026 | 175 | 91 | 57 | 25 | 23 | 63 | 54 | 1 | 80 | 14 |
| March 31, 2025 | 176 | 104 | 68 | 19 | 19 | 67 | 47 | 1 | 77 | 12 |
| March 31, 2024 | — | — | — | — | — | — | — | — | — | — |
| March 31, 2023 | — | — | — | — | — | — | — | — | — | — |
| March 31, 2022 | — | — | — | — | — | — | — | — | — | — |
